Vascular checkpoints for cancer immunotherapy

Santos Mañes
Centro Nacional de Biotecnologia (CNB) [Madrid, Spain]
Date: 04/07/2019
Time: 12:30:00
Salón de actos del Centro de Investigación del Cáncer
Xosé Bustelo
Cancer immunotherapy is based on the ability of immune cells, and in particular of T lymphocytes, to recognize neoantigens in tumor cells, and thus to cause their destruction. During their evolution, tumors develop multiple strategies that suppress T-cell based immune responses to evade their immunodestruction. One of these evasive mechanisms is based on the selective blockade of the entry of effector T lymphocytes into the tumor microenvironment (TME), thus